FDA approves plerixafor (in combination with G-CSF) to mobilize hematopoietic stem cells in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM)

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Practice & Guidelines

Practice Management & Reimbursement

FDA Drug Alerts

FDA approves plerixafor (in combination with G-CSF) to mobilize hematopoietic stem cells in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM)

On December 15, 2008, the U. S. Food and Drug Administration approved plerixafor, solution for subcutaneous injection, (MozobilTM, Genzyme Corp.) for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

The efficacy and safety of plerixafor in combination with G-CSF in NHL and MM were evaluated in two placebo-controlled studies (Studies 1 and 2). Patients were randomized to receive either plerixafor 0.24 mg/kg or placebo each evening prior to apheresis. All patients received G-CSF 10 micrograms/kg daily for 4 days prior to the first dose of plerixafor or placebo and prior to apheresis. Results from 298 patients with NHL from study 1 and 302 patients with MM from study 2 were analyzed.

In Study 1, 59% of patients with NHL who were mobilized with plerixafor and G-CSF collected greater than or equal to 5 X 106 CD34+ cells/kg from the peripheral blood in four or fewer apheresis sessions compared with 20% of patients who were mobilized with placebo and G-CSF (p < 0.001). The median number of days to reach greater than or equal to 5 x 106 CD34+ cells/kg was 3 days for the plerixafor group and not evaluable for the placebo group.

In Study 2, 72% of patients with MM who were mobilized with plerixafor and G-CSF collected greater than or equal to 6 X 106 CD34+ cells/kg from the peripheral blood in two or fewer apheresis sessions compared with 34% of patients who were mobilized with placebo and G-CSF (p <0.001). The median number of days to reach greater than or equal to 6 x 106 CD34+ cells/kg was 1 day for the plerixafor group and 4 days for the placebo group.

Safety data for plerixafor in combination with G-CSF were obtained from 983 patients enrolled in 16 clinical studies (593 patients enrolled in randomized Studies 1 and 2 plus 410 patients enrolled in 14 additional non-randomized studies). Patients were primarily treated with plerixafor at daily doses of 0.24 mg/kg SC. Median exposure to plerixafor was 2 days (range 1 to 7 days). The most common adverse reactions (greater than or equal to 10%) reported in patients who received plerixafor in conjunction with G-CSF that were more frequent than in patients who received placebo were diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness and vomiting. Prescribing physicians and patients should be aware of the potential for tumor cell mobilization in leukemia patients, increased circulating leukocytes and decreased platelet counts, splenic enlargement, and fetal harm when administered to pregnant women.

Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available at http://www.fda.gov/cder/foi/label/2008/022311lbl.pdf.